Closed · RFA-DA-23-002 · CFDA 93.279 · Discretionary
Increasing Immediate Engagement and Retention in HIV Treatment with Substance Users (R01- Clinical Trials Required)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- August 11, 2022
- Close date
- -
- Expected awards
The verdict
Increasing Immediate Engagement and Retention in HIV Treatment with Substance Users (R01- Clinical Trials Required) is a closed discretionary listing from National Institutes of Health that offered Varies by applicant. Future funding cycles may be published under the same CFDA number.
- Varies
- award range
- Closed
- application status
- 93.279
- CFDA program
Opportunity snapshot. This Grants.gov announcement - Increasing Immediate Engagement and Retention in HIV Treatment with Substance Users (R01- Clinical Trials Required) - is cataloged under number RFA-DA-23-002 and tied to CFDA assistance listing 93.279, posted by National Institutes of Health. Grants.gov currently shows the opportunity as closed, first posted on April 6, 2022. The funding category is Discretionary, delivered as a grant.
Award economics. The award range on file is Varies by applicant. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity closed on August 11, 2022. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.
Award Range
Varies by applicant
Close Date
August 11, 2022
Posted
April 6, 2022
Instrument
Grant
Description
oEnsuring all PLWH have rapid access to care, especially in resource-limited settings, remains a key challenge to the success of HIV care/treatment efforts. Same day or other rapid treatment initiation may be available, but patients may be concerned that other needs will make treatment difficult or they may face delays related to the enrollment process for treatment support mechanisms (e.g., ADAP, Ryan White, Medicaid). Similarly, long-term retention in HIV care and sustained achievement of viral suppression can be challenging even when ARV is introduced at or close to HIV diagnosis. Existing practices such as Strengths-Based Case Management and Patient Navigation often demonstrate a lack of efficacy among people with SUD. Persons with SUD and HIV often present clinical complexities and engagement with multiple services may be necessary; where reducing and eliminating barriers (i.e. structural or individual) to immediate linkage to care is critical to minimizing time between diagnosis and treatment and can lead to achieving Ending the Epidemic goals. Even with rapid ARV uptake, this population may need additional supports to remain continuously engaged in care. There is a need to develop and test evidence-based interventions at the systemic, organizational, and/or provider levels that can reduce the time between diagnosis and treatment while also retaining persons with SUD in HIV and SUD care.
Eligibility
Grants.gov lists this opportunity under eligibility category codes 00, 01, 02, 04, 05, 06, 07, 08, 11, 12, 13, 20, 22, 23, 25. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Parent Grant Program
Drug Abuse Research Programs
National Institutes of Health
Agency Contact
NIH OER Webmaster OERWebmaster03@od.nih.gov
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
Related
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |